Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 1.00 |
| ▸ | MAPK3 | P27361 | 17/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 17/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 2/20 | 1.00 |
| ▸ | CIT | O14578 | 2/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 1.00 |
| ▸ | STK10 | O94804 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | RAF1 | P04049 | 2/20 | 1.00 |
| ▸ | ERBB3 | P21860 | 2/20 | 1.00 |
| ▸ | JAK1 | P23458 | 2/20 | 1.00 |
| ▸ | ACVR1B | P36896 | 2/20 | 1.00 |
| ▸ | TGFBR1 | P36897 | 2/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 2/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 2/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 2/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 1.00 |
| ▸ | MAP3K19 | Q56UN5 | 2/20 | 1.00 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2467603 | 1.00 | BRAF (1.00) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL2467604 | 1.00 | BRAF (1.00) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL31060883 | 1.00 | BRAF (1.00) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL15526774 | 1.00 | BRAF (1.00) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL19530328 | 0.91 | BRAF (0.84) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL4134773 | 0.91 | BRAF (1.00) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL4134774 | 0.91 | BRAF (1.00) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL10000524 | 0.91 | BRAF (0.83) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL4137485 | 0.90 | BRAF (0.82) | BRAFMAPK3MAPK1BMPR1BCIT | |
| SCHEMBL4137490 | 0.90 | BRAF (0.82) | BRAFMAPK3MAPK1BMPR1BCIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1401 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636376-B2 | Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors | IN3BIO LTD. (BM) | 2026-05-26 | — | — | US | claimed |
| EP-4735598-A2 | NRAS GENE KNOCKOUT FOR TREATMENT OF CANCER | Christiana Care Gene Editing Institute, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | claimed |
| US-12605371-B2 | Combination therapy for cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-04-21 | — | — | US | claimed |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-03-24 | — | — | US | claimed |
| US-12522872-B2 | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-01-13 | — | — | US | claimed |
| EP-4658321-A1 | P-SELECTIN TARGETED NANOPARTICLES AND USES THEREOF | Ramot at Tel-Aviv University Ltd. (IL) | 2025-12-10 | — | — | EP | claimed |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-11-06 | — | — | US | claimed |
| EP-4587026-A1 | COMBINATIONS | Recurium IP Holdings, LLC (US) | 2025-07-23 | — | — | EP | claimed |
| US-12351625-B2 | Therapeutic antibodies against osteopontin | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-07-08 | — | — | US | claimed |
| US-11439648-B2 | Use of topical BRAF inhibitor compositions for treatment of radiation dermatitis | LUTRIS PHARMA LTD. (IL) | 2022-09-13 | — | — | US | claimed |
| EP-3473250-B1 | DDR2 MUTATIONS AS TARGETABLE FEATURES OF MELANOMA OR BASAL CELL CARCINOMA | QUEST DIAGNOSTICS INVEST INC (US) | 2022-08-17 | — | — | EP | claimed |
| CN-114867746-A | Therapeutic antibodies against osteopontin | 小利兰·斯坦福大学董事会 | 2022-08-05 | — | — | CN | claimed |
| US-20220195408-A1 | COMBINATION CHEMOTHERAPY FOR THE TREATMENT OF CANCER | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2022-06-23 | — | — | US | claimed |
| WO-2022125941-A1 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH BRAF INHIBITORS AND/OR MEK INHIBITORS | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | claimed |
| EP-4010369-A1 | THERAPEUTIC ANTIBODIES AGAINST OSTEOPONTIN | The Board of Trustees of the Leland Stanford Junior University (US) | 2022-06-15 | — | — | EP | claimed |
| US-20220177842-A1 | METHOD FOR LONG-TERM EX VIVO MAINTENANCE OR EXPANSION OF HUMAN ERYTHROBLAST, HUMAN MEGAKARYOCYTE-ERYTHROID PROGENITOR, OR HUMAN COMMON MYELOID PROGENITOR CELL AND APPLICATION THEREOF | OCGENE THERAPEUTICS CORPORATION | 2022-06-09 | — | — | US | claimed |
| EP-4003332-A1 | PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND USE THEREOF FOR PREVENTING AND/OR TREATING DISEASE | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2022-06-01 | — | — | EP | claimed |
| US-20220142979-A1 | PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND USE THEREOF FOR PREVENTING AND/OR TREATING DISEASE | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-05-12 | — | — | US | claimed |
| US-11286469-B2 | Combination chemotherapy for the treatment of cancer | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2022-03-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142979-A1 | PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND USE THEREOF FOR PREVENTING AND/OR TREATING DISEASE | MDM2, TP53, BRCA1 | BRAF 707/4885MAPK3 2967/4885MAPK1 2419/4885 |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | BRAF 3140/4885MAPK3 4296/4885MAPK1 4804/4885 |
| US-12636376-B2 | Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors | BRAF, TTK, CKS1B | BRAF 1/4885MAPK3 420/4885MAPK1 824/4885 |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BRAF, SRMS, MAPK3 | BRAF 1/4885MAPK3 3/4885MAPK1 84/4885 |
| US-11439648-B2 | Use of topical BRAF inhibitor compositions for treatment of radiation dermatitis | BRAF, NRAS, RAF1 | BRAF 1/4885MAPK3 22/4885MAPK1 61/4885 |
| US-12605371-B2 | Combination therapy for cancer | BRAF, TFPI, HGFAC | BRAF 1/4885MAPK3 61/4885MAPK1 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.